You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

liptruzet Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Liptruzet patents expire, and what generic alternatives are available?

Liptruzet is a drug marketed by Organon and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

US Patents and Regulatory Information for liptruzet

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for liptruzet

International Patents for liptruzet

See the table below for patents covering liptruzet around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 9800121 ⤷  Try a Trial
Germany 122004000026 ⤷  Try a Trial
Australia 725424 ⤷  Try a Trial
Czech Republic 288891 Farmaceutický prostředek s hypocholesterolemními účinky (Pharmaceutical preparation exhibiting hypocholesterolaemic activity) ⤷  Try a Trial
Czech Republic 294740 Krystalická forma IV atorvastatinu nebo jeho hydrátu, farmaceutický přípravek obsahující tuto krystalickou formu IV atorvastatinu a její použití v lékařství (Crystalline form IV atorvastatin or hydrate thereof, pharmaceutical composition containing such a crystalline form IV atorvastatin and its use in medicine) ⤷  Try a Trial
Austria 208375 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for liptruzet

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 03C0028 France ⤷  Try a Trial PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599 C300132 Netherlands ⤷  Try a Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION: RVG 28626 20030418; FIRST REGISTRATION: DE 54486.00.00, 54487.00.00, 54488.00.00, 54489.00.00 20021017
0720599 CR 2014 00048 Denmark ⤷  Try a Trial PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
0720599 91160 Luxembourg ⤷  Try a Trial 91160, EXPIRES: 20190914
0720599 C00720599/02 Switzerland ⤷  Try a Trial FORMER OWNER: SCHERING CORPORATION, US
1003503 05C0048 France ⤷  Try a Trial PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.